美国安进地舒单抗注射液的效果好不好

It is a new type of RANKL inhibitor developed by Amgen. It is a fully human monoclonal IgG2 antibody of RANKL. It has high affinity and specificity for the soluble, transmembrane form of human RANKL. In patients with giant cell tumors of bone, inhibition of RANKL secreted by tumor stromal components with denosumab significantly reduced or eliminated osteoclast-like tumor-associated giant cells. As a result, osteolysis is reduced, giant cell tumor progression is slowed, and the proliferative matrix is ​​replaced by dense nonproliferative, differentiated woven new bone, thereby improving clinical outcomes.

Is American Amgen’s denosumab injection effective? The study included 1,597 patients, including the most common form of lung cancer, accounting for 49%. The study compared the delay or prevention of skeletal-related events between denosumab and zoledronic acid in patients with advanced cancer with bone metastases (excluding breast and prostate cancer). The results showed that the median time to skeletal-related events in the denosumab group was 21.4 months, and that of zoledronic acid was 15.4 months. Desosumab significantly delayed the onset of bone complications by 6 months.

As one of the world's largest biopharmaceutical companies, Amgen is a leader in the global biopharmaceutical industry. It has strong R&D capabilities and product advantages. It insists on developing in the field of biotechnology for disease treatment. Its main fields include human genome, cancer, neuroscience and small molecule chemistry. According to Medical Travel, the current specification of Amgen in the United States is 120 mg, and the price is only $1,450, which is more suitable for patients to use for a long time. Since the exchange rate has been fluctuating for a long time and the price is unstable, please contact Medical Travel for details.